Coherus Oncology (FRA:8C5) FCF Margin %: -470.24% (As of Mar. 2026)

What is Coherus Oncology FCF Margin %?

Coherus Oncology FRA:8C5 -4.27% 45 FCF Margin % is -470.24% as of Mar. 2026. GuruFocus rates FRA:8C5 with a GF Score™ of 45/100 and a GF Value™ of €0.69 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 956 Biotechnology companies, Coherus Oncology ranks worse than 67.36% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Coherus Oncology's Free Cash Flow for the three months ended in Mar. 2026 was €-50.07 Mil. Coherus Oncology's Revenue for the three months ended in Mar. 2026 was €10.65 Mil. Therefore, Coherus Oncology's FCF Margin % for the quarter that ended in Mar. 2026 was -470.24%.

As of today, Coherus Oncology's current FCF Yield % is -78.99%.

The historical rank and industry rank for Coherus Oncology's FCF Margin % or its related term are showing as below:

FRA:8C5' s FCF Margin % Range Over the Past 10 Years
Min: -13165.75 Med: -77.46 Max: 30.88
Current: -364.47

During the past 13 years, the highest FCF Margin % of Coherus Oncology was 30.88%. The lowest was -13165.75%. And the median was -77.46%.

FRA:8C5's FCF Margin % is ranked worse than
67.36% of 956 companies
in the Biotechnology industry
Industry Median: -85.21 vs FRA:8C5: -364.47

Coherus Oncology FCF Margin % Related Terms

Coherus Oncology FCF Margin % Historical Data

* Premium members only.

The historical data trend for Coherus Oncology's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Coherus Oncology FCF Margin % Chart

Coherus Oncology Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

FCF Margin %

Get a 7-Day Free Trial

-11.86

-115.22

-68.09

-77.46

-328.45

Coherus Oncology Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
FCF Margin %	Get a 7-Day Free Trial															-339.86	-454.78	-400.50	-154.65	-470.24

FRA:8C5 vs TARA, KPTI, CNTN: FCF Margin % Comparison

For the Biotechnology subindustry, Coherus Oncology's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Coherus Oncology FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Coherus Oncology's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Coherus Oncology's FCF Margin % falls into.

Save Embed

45GF Score

Coherus Oncology Inc FRA:8C5

FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Coherus Oncology FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Coherus Oncology's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2025 )	/	Revenue (A: Dec. 2025 )
	=	-118.29	/	36.015
	=	-328.45 %

Coherus Oncology's FCF Margin for the quarter that ended in Mar. 2026 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2026 )	/	Revenue (Q: Mar. 2026 )
	=	-50.071	/	10.648
	=	-470.24 %

Frequently Asked Questions Learn more about FCF Margin % →

What does a FCF Margin % of -470.24% mean?

Coherus Oncology (FRA:8C5) has a FCF Margin % of -470.24% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Coherus Oncology and its competitors. According to the industry distribution chart, Coherus Oncology ranks #644 out of 956 companies in the Biotechnology industry, placing it in the top 67.4%.

Is Coherus Oncology's FCF Margin % too high?

Coherus Oncology's current FCF Margin % is -470.24%. Based on the distribution chart, Coherus Oncology ranks #644 out of 956 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Coherus Oncology has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Coherus Oncology's FCF Margin % compare to TARA and KPTI?

According to the Biotechnology industry distribution chart, Coherus Oncology ranks #644 out of 956 companies for FCF Margin %. This places Coherus Oncology in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good FCF Margin % for a Biotechnology company?

A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high FCF Margin % mean?

A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Coherus Oncology and its competitors. Coherus Oncology's current FCF Margin % is -470.24%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Coherus Oncology stock overvalued right now?

Based on GuruFocus' analysis, Coherus Oncology (FRA:8C5) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.69, compared to a current price of €1.26 — trading 82.2% above its estimated fair value. The current FCF Margin % is -470.24%. Coherus Oncology's overall GF Score™ is 45/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is FCF Margin % calculated?

FCF Margin % is calculated from a company's financial statements. For Coherus Oncology (FRA:8C5), the current FCF Margin % is -470.24% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Coherus Oncology (FRA:8C5) Overvalued in 2026?

Based on GuruFocus' analysis, Coherus Oncology stock appears to be overvalued. The current stock price of €1.26 is trading 82.2% above its estimated GF Value™ of €0.69. GuruFocus considers Coherus Oncology to be Significantly Overvalued.

Key valuation signals for FRA:8C5:

FCF Margin %: -470.24%
GF Value™: €0.69 vs. price of €1.26 (82.2% above fair value)
GF Score™: 45/100 with 6 warning signs

No single metric tells the full story. See the FRA:8C5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Coherus Oncology Business Description

Industry Healthcare Biotechnology

Comparable Companies TARA KPTI CNTN RNA QTTB AVXL SLGL CAMP CDXS KROS VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges CHRS:USA

Address 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, USA, 94065

Website https://www.coherus.com

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.

45GF Score

Get the complete analysis for FRA:8C5

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.26

Price

€0.69

GF Value

View FRA:8C5 Analysis

See FCF Margin % data for all stocks →